APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients.

Trial Profile

APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Apricoxib; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms APRiCOT-L
  • Most Recent Events

    • 01 Apr 2014 Results published in the Journal of Thoracic Oncology.
    • 06 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top